vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and iQSTEL Inc (IQST). Click either name above to swap in a different company.
iQSTEL Inc is the larger business by last-quarter revenue ($84.2M vs $44.9M, roughly 1.9× AbCellera Biologics Inc.). iQSTEL Inc runs the higher net margin — -3.2% vs -19.9%, a 16.7% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs -14.9%). iQSTEL Inc produced more free cash flow last quarter ($-1.2M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 28.0%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
iQSTEL Inc is a technology holding company operating three core segments: telecommunications, Internet of Things (IoT), and fintech. It offers connectivity services, smart IoT monitoring solutions, and digital financial tools, mainly serving small and medium-sized enterprises and retail customers in North and South American markets.
ABCL vs IQST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $84.2M |
| Net Profit | $-8.9M | $-2.7M |
| Gross Margin | — | 3.5% |
| Operating Margin | -63.7% | -2.9% |
| Net Margin | -19.9% | -3.2% |
| Revenue YoY | 788.4% | -14.9% |
| Net Profit YoY | 73.9% | -44.5% |
| EPS (diluted) | $-0.03 | $-0.92 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $84.2M | ||
| Q3 25 | $9.0M | $102.9M | ||
| Q2 25 | $17.1M | $72.2M | ||
| Q1 25 | $4.2M | $57.6M | ||
| Q4 24 | $5.0M | $98.9M | ||
| Q3 24 | $6.5M | $54.2M | ||
| Q2 24 | $7.3M | $78.6M | ||
| Q1 24 | $10.0M | $51.4M |
| Q4 25 | $-8.9M | $-2.7M | ||
| Q3 25 | $-57.1M | $-2.3M | ||
| Q2 25 | $-34.7M | $-2.3M | ||
| Q1 25 | $-45.6M | $-1.1M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | $-51.1M | $-773.0K | ||
| Q2 24 | $-36.9M | $-2.0M | ||
| Q1 24 | $-40.6M | $-580.2K |
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 2.7% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 3.4% | ||
| Q4 24 | — | 2.7% | ||
| Q3 24 | — | 3.7% | ||
| Q2 24 | — | 2.8% | ||
| Q1 24 | — | 2.7% |
| Q4 25 | -63.7% | -2.9% | ||
| Q3 25 | -851.8% | -0.5% | ||
| Q2 25 | -290.2% | -0.9% | ||
| Q1 25 | -1479.6% | -1.0% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | -1439.4% | -0.1% | ||
| Q2 24 | -1276.2% | -0.4% | ||
| Q1 24 | -551.5% | -0.4% |
| Q4 25 | -19.9% | -3.2% | ||
| Q3 25 | -637.8% | -2.3% | ||
| Q2 25 | -203.3% | -3.3% | ||
| Q1 25 | -1077.2% | -2.0% | ||
| Q4 24 | — | -1.9% | ||
| Q3 24 | -785.4% | -1.4% | ||
| Q2 24 | -504.3% | -2.5% | ||
| Q1 24 | -408.0% | -1.1% |
| Q4 25 | $-0.03 | $-0.92 | ||
| Q3 25 | $-0.19 | $-0.68 | ||
| Q2 25 | $-0.12 | $-0.82 | ||
| Q1 25 | $-0.15 | $-0.44 | ||
| Q4 24 | — | $-1.19 | ||
| Q3 24 | $-0.17 | $-0.40 | ||
| Q2 24 | $-0.13 | $-0.90 | ||
| Q1 24 | $-0.14 | $-0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $2.2M |
| Total DebtLower is stronger | — | $4.1M |
| Stockholders' EquityBook value | $966.9M | $16.3M |
| Total Assets | $1.4B | $51.1M |
| Debt / EquityLower = less leverage | — | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | $2.2M | ||
| Q3 25 | $83.2M | $2.3M | ||
| Q2 25 | $92.4M | $2.0M | ||
| Q1 25 | $159.3M | $1.1M | ||
| Q4 24 | $156.3M | $2.5M | ||
| Q3 24 | $126.6M | $2.1M | ||
| Q2 24 | $148.3M | $797.2K | ||
| Q1 24 | $123.6M | $2.7M |
| Q4 25 | — | $4.1M | ||
| Q3 25 | — | $2.7M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $3.5M | ||
| Q4 24 | — | $2.5M | ||
| Q3 24 | — | $3.2M | ||
| Q2 24 | — | $2.5M | ||
| Q1 24 | — | $194.0K |
| Q4 25 | $966.9M | $16.3M | ||
| Q3 25 | $964.0M | $17.9M | ||
| Q2 25 | $1.0B | $14.3M | ||
| Q1 25 | $1.0B | $11.6M | ||
| Q4 24 | $1.1B | $11.9M | ||
| Q3 24 | $1.1B | $8.1M | ||
| Q2 24 | $1.1B | $7.6M | ||
| Q1 24 | $1.1B | $8.4M |
| Q4 25 | $1.4B | $51.1M | ||
| Q3 25 | $1.4B | $46.9M | ||
| Q2 25 | $1.4B | $51.4M | ||
| Q1 25 | $1.3B | $42.0M | ||
| Q4 24 | $1.4B | $79.0M | ||
| Q3 24 | $1.4B | $32.4M | ||
| Q2 24 | $1.4B | $30.0M | ||
| Q1 24 | $1.5B | $22.1M |
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.31× | ||
| Q1 25 | — | 0.31× | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $-1.2M |
| Free Cash FlowOCF − Capex | $-44.6M | $-1.2M |
| FCF MarginFCF / Revenue | -99.4% | -1.5% |
| Capex IntensityCapex / Revenue | 21.9% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | $-4.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | $-1.2M | ||
| Q3 25 | $-52.6M | $-953.0K | ||
| Q2 25 | $-32.4M | $257.7K | ||
| Q1 25 | $-11.6M | $-1.9M | ||
| Q4 24 | $-108.6M | $-403.7K | ||
| Q3 24 | $-28.9M | $625.0K | ||
| Q2 24 | $-30.0M | $-2.6M | ||
| Q1 24 | $-41.7M | $-536.9K |
| Q4 25 | $-44.6M | $-1.2M | ||
| Q3 25 | $-61.5M | $-969.2K | ||
| Q2 25 | $-45.8M | $211.7K | ||
| Q1 25 | $-22.2M | $-2.0M | ||
| Q4 24 | $-187.0M | $-421.3K | ||
| Q3 24 | $-47.4M | $594.5K | ||
| Q2 24 | $-50.1M | $-2.6M | ||
| Q1 24 | $-65.8M | $-608.5K |
| Q4 25 | -99.4% | -1.5% | ||
| Q3 25 | -687.0% | -0.9% | ||
| Q2 25 | -267.9% | 0.3% | ||
| Q1 25 | -524.0% | -3.4% | ||
| Q4 24 | -3702.8% | -0.4% | ||
| Q3 24 | -728.4% | 1.1% | ||
| Q2 24 | -683.8% | -3.4% | ||
| Q1 24 | -661.5% | -1.2% |
| Q4 25 | 21.9% | 0.0% | ||
| Q3 25 | 99.7% | 0.0% | ||
| Q2 25 | 78.2% | 0.1% | ||
| Q1 25 | 251.1% | 0.1% | ||
| Q4 24 | 1552.7% | 0.0% | ||
| Q3 24 | 284.6% | 0.1% | ||
| Q2 24 | 274.6% | 0.0% | ||
| Q1 24 | 242.5% | 0.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABCL
Segment breakdown not available.
IQST
| USA | $53.2M | 63% |
| Other | $29.9M | 35% |
| Switzerland | $1.1M | 1% |
